Last reviewed · How we verify
ARQ 197 plus erlotinib
ARQ 197 is a small molecule inhibitor of c-MET, and when combined with erlotinib, targets the EGFR and c-MET pathways.
ARQ 197 is a small molecule inhibitor of c-MET, and when combined with erlotinib, targets the EGFR and c-MET pathways. Used for Non-small cell lung cancer, Other cancers with EGFR and c-MET overexpression.
At a glance
| Generic name | ARQ 197 plus erlotinib |
|---|---|
| Also known as | Tivantinib |
| Sponsor | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) |
| Drug class | c-MET inhibitor, EGFR inhibitor |
| Target | c-MET, EGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
The combination of ARQ 197 and erlotinib targets the EGFR and c-MET pathways, which are involved in the growth and spread of cancer cells. This dual inhibition can potentially lead to a more effective treatment of certain types of cancer.
Approved indications
- Non-small cell lung cancer
- Other cancers with EGFR and c-MET overexpression
Common side effects
- Diarrhea
- Rash
- Fatigue
- Nausea
- Vomiting
Key clinical trials
- Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer (PHASE3)
- An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols (PHASE1, PHASE2)
- Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery (PHASE2)
- Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (PHASE2)
- A Study of ARQ 197 in Combination With Erlotinib (PHASE1)
- A Study of ARQ 197 in Combination With Erlotinib (PHASE1)
- A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib (PHASE3)
- ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: